Ocugen (OCGN) Net Cash Flow (2014 - 2026)
Ocugen (OCGN) reported Net Cash Flow of $13.2 million for Q1 2026, up 163.68% on a YoY basis from $5.0 million in Q1 2025, and up 194.21% quarter-over-quarter from -$14.0 million in Q4 2025.
Ocugen (OCGN) Net Cash Flow (2014 - 2026) Analysis & Trends
Ocugen has reported Net Cash Flow for 13 years, with the latest figure at $13.2 million in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow rose 163.68% year-over-year to $13.2 million; the trailing twelve-month figure through Mar 2026 stood at -$6.1 million (down 151.7% YoY), and the FY2025 full-year result was -$39.9 million, down 306.65% from the prior year.
- Net Cash Flow for Q1 2026 stood at $13.2 million, up from -$14.0 million in the prior quarter.
- The five-year high for Net Cash Flow was $34.8 million in Q1 2022, with the low at -$24.0 million in Q4 2022.
- Historically, Net Cash Flow has averaged -$3.7 million across 5 years, with a median of -$10.8 million in 2025.
- The largest YoY upside for Net Cash Flow was 241.31% in 2024 against a maximum downside of 547.18% in 2024.
- Ocugen's Net Cash Flow stood at -$24.0 million in 2022, then soared by 41.72% to -$14.0 million in 2023, then jumped by 241.31% to $19.8 million in 2024, then plunged by 170.69% to -$14.0 million in 2025, then soared by 194.21% to $13.2 million in 2026.
- The last three Net Cash Flow figures came in at $13.2 million (Q1 2026), -$14.0 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 664,983.53 |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - | 13.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.18 Mn |
| Mar 31, 2026 | 13.18 Mn |
| Dec 31, 2025 | -13.99 Mn |
| Dec 31, 2025 | -13.99 Mn |
| Sep 30, 2025 | 5.51 Mn |
| Sep 30, 2025 | 5.51 Mn |
| Jun 30, 2025 | -10.76 Mn |
| Jun 30, 2025 | -10.76 Mn |
| Mar 31, 2025 | -20.70 Mn |
| Mar 31, 2025 | -20.70 Mn |
| Dec 31, 2024 | 19.80 Mn |
| Dec 31, 2024 | 19.80 Mn |
| Sep 30, 2024 | 23.01 Mn |
| Sep 30, 2024 | 23.01 Mn |
| Jun 30, 2024 | -10.38 Mn |
| Jun 30, 2024 | -10.38 Mn |
| Mar 31, 2024 | -13.09 Mn |
| Mar 31, 2024 | -13.09 Mn |
| Dec 31, 2023 | -14.01 Mn |
| Dec 31, 2023 | -14.01 Mn |